A Study to Evaluate Valbenazine for Tardive Dyskinesia
Phase 4
50
about 1.7 years
18+
19 sites in AR, CA, FL +5
What this study is about
Researchers are testing whether valbenazine helps people with tardive dyskinesia who are still experiencing symptoms, even after stopping a VMAT2 inhibitor. The trial will last 609 days and involve approximately 50 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Valbenazine
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
valbenazine
oral (Oral Capsule)
Primary: Change from Baseline in the Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score (AIMS 1-7) at Week 24
Secondary: Change from Baseline in the Clinical Global Impression of Severity - Tardive Dyskinesia (CGI-TD-S) Score at Week 24, Change from Baseline in the EuroQol-Visual Analogue Scale (EQ-VAS) at Week 24, Change from Baseline in the Tardive Dyskinesia Impact Scale (TDIS) at Week 24
Psychiatry / Mental Health